#pharma innovation

Biologics manufacturing is undergoing a fundamental shift as cell and gene therapies, antibody-drug conjugates, and RNA-based modalities transition into commercial-scale production. Advances in continuous bioprocessing, process intensification, and manufacturing capacity expansion strategies for viral vector and RNA manufacturing are central to this evolution. Benchmarks for monoclonal antibodies and biosimilars add further complexity. Submissions are invited on process development, scale-up strategies, quality by design, and analytical methods for next-generation biopharmaceuticals.

• Cell and gene therapy manufacturing
• Continuous bioprocessing
• Scale-up
• Quality by design (QbD)
• ATMP
• Cell Culture Technologies

Single-use technologies have become integral to biopharmaceutical manufacturing, enabling faster facility set-up, reduced cross-contamination risk, and greater flexibility for multiproduct sites. Their adoption is expanding into demanding applications such as antibody-drug conjugate production and cell and gene therapy, where stringent containment and scalability requirements apply. Submissions are invited on bioreactor design, fluid management systems, in-line sensing and monitoring, extractables and leachables, and end-of-life considerations for single-use components.

• Single-use bioprocessing
• Single-use bioreactors
• Extractables & leachables
• Single-use sensors

Pharmaceutical production must reduce its environmental footprint without compromising quality or efficiency. Material selection for raw and process materials, production supplies, and packaging— aligned with GMP and performance requirements — is a key lever to cut value-chain emissions.  Submissions are invited on sustainable synthesis, waste minimisation, solvent recovery, green process design, and integration of environmental metrics into pharma process development and regulatory submissions.

• Low-emission material selection
• Solvent substitution & recovery
• Sustainable pharmaceutical manufacturing
• Green process design
• Environmental metrics (LCA / PMI) 

New equipment concepts and process technologies are redefining standards in pharmaceutical manufacturing. Innovations in unit-operation hardware, materials of construction, aseptic processing equipment, containment solutions, and integrated PAT-enabled skids are gaining traction as manufacturers modernize established batch operations and address robustness, cleanability, and compliance demands.  Submissions are invited on equipment development, engineering design and qualification, lifecycle and maintenance concepts as well as regulatory acceptance of novel pharmaceutical manufacturing technologies at both solid-dose and sterile production scales.

• Aseptic processing equipment
• Containment & operator safety
• In-line sensing & verification 
• Novel unit operations
• Equipment qualification & compliance 

Automation and robotics are advancing rapidly across pharmaceutical production, from aseptic fill-finish and packaging to compounding and in-process quality control. Collaborative robots, automated visual inspection systems, and robotic handling in containment-critical environments are reshaping facility design and operational benchmarks. Submissions are invited on robotics integration, automated process control, validation of automated systems, and human-machine interaction in GMP-regulated pharmaceutical manufacturing environments.

• Pharmaceutical robotics
• Aseptic fill-finish automation
• Collaborative robots (cobots)
• Automated visual inspection
• GMP-compliant automation
• Automated process control
• Validation of automated systems

Modular and flexible production concepts are gaining significance in pharmaceutical manufacturing as sites seek faster reconfiguration, shorter changeover times, and the ability to handle multiple product types within a single facility. Plug-and-play process modules, standardised interfaces, and reconfigurable cleanroom systems are enabling more agile responses to shifting demand and product portfolios. Submissions are invited on modular plant design, process module standardisation, flexible fill-finish, and regulatory strategies for modular pharmaceutical facilities.

• Modular pharmaceutical manufacturing
• Flexible production systems
• Plug-and-play process modules
• Reconfigurable cleanroom design
• Multiproduct facility strategies
• Flexible fill-finish

Pharmaceutical packaging is evolving well beyond containment, with primary and secondary packaging increasingly integrated into final processing workflows. Serialisation, tamper-evidence, patient-centric design, and barrier systems for parenteral and biological products are raising both technical and regulatory benchmarks. Submissions are invited on primary packaging materials and formats, filling and closing technologies, integrated end-of-line processing, serialisation implementation, and packaging qualification for novel drug products and delivery systems.

• Primary & secondary pharmaceutical packaging
• Serialisation & track-and-trace
• Parenteral & biological product packaging
• Integrated fill-finish & end-of-line processing
• Tamper-evidence & barrier systems
• Patient-centric packaging design
• Packaging qualification & regulatory compliance

Pharmaceutical supply chains face heightened demands for resilience, traceability, and compliance as product portfolios grow more complex and geopolitical pressures expose fragilities in established networks. Cold chain management for biologics and advanced therapies, serialisation under evolving regulatory frameworks, and end-to-end supply chain visibility are central challenges. Submissions are invited on cold chain technology, track-and-trace implementation, supply chain risk management, and logistics strategies for temperature-sensitive drug products.

• Serialisation & track-and-trace
• Temperature-controlled logistics
• Biologics & advanced therapy distribution
• Supply chain resilience
• Supply chain risk management
• End-to-end supply chain visibility